RA
TTPH

Royce & Associates’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Royce & Associates’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-26,395
Closed -$254K – 1206
2019
Q2 		$254K Hold
26,395
– – ﹤0.01% 980
2019
Q1 		$707K Buy
26,395
+2,550
+11% +$64.9K 0.01% 890
2018
Q4 		$539K Hold
23,845
– – ﹤0.01% 927
2018
Q3 		$1.32M Buy
23,845
+16,055
+206% +$1.03M 0.01% 888
2018
Q2 		$556K Buy
+7,790
New +$550K ﹤0.01% 1013

Other funds holding TTPH

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Royce & Associates's TTPH Position: Q3 2019 in Review

Royce & Associates sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2019, closing a stake of 26,395 shares — an estimated $254K sold.

Royce & Associates first reported a position in TTPH in Q2 2018 and held it in 5 quarters. The position peaked at $1.32M in Q3 2018. 26 funds tracked by Wall St. Rank hold TTPH as of Q3 2019.

  • Royce & Associates reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Royce & Associates sold 26,395 Tetraphase Pharmaceuticals, Inc. shares in Q3 2019, an estimated $254K.
  • Royce & Associates first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2018 and held it in 5 quarters.
  • Royce & Associates's Tetraphase Pharmaceuticals, Inc. position peaked at $1.32M in Q3 2018.
  • 26 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2019.

Based on Royce & Associates's 13F filing for Q3 2019, filed 13 Nov 2019.